SSA
QNCX icon

Schonfeld Strategic Advisors’s Quince Therapeutics QNCX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-137
Closed -$36K – 2934
2022
Q3 		$36K Sell
137
-159
-54% -$60.6K ﹤0.01% 2676
2022
Q2 		$131K Buy
296
+196
+196% +$139K ﹤0.01% 2066
2022
Q1 		$123K Buy
+100
New +$136K ﹤0.01% 2170
2021
Q3 		– Sell
-39
Closed -$413K – 2410
2021
Q2 		$413K Buy
+39
New +$327K ﹤0.01% 1286
2020
Q4 		– Sell
-140
Closed -$1.4M – 1825
2020
Q3 		$1.4M Buy
140
+72
+106% +$655K 0.03% 614
2020
Q2 		$631K Buy
+68
New +$623K 0.02% 731
2019
Q3 		– Sell
-58
Closed -$489K – 1196
2019
Q2 		$489K Buy
+58
New +$347K 0.02% 635

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Schonfeld Strategic Advisors's QNCX Position: Q4 2022 in Review

Schonfeld Strategic Advisors sold out of Quince Therapeutics (QNCX) in Q4 2022, closing a stake of 137 shares — an estimated $36K sold.

Schonfeld Strategic Advisors first reported a position in QNCX in Q2 2019 and held it in 7 quarters. The position peaked at $1.4M in Q3 2020. 48 funds tracked by Wall St. Rank hold QNCX as of Q4 2022.

  • Schonfeld Strategic Advisors reported no remaining Quince Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 137 Quince Therapeutics shares in Q4 2022, an estimated $36K.
  • Schonfeld Strategic Advisors first reported a position in Quince Therapeutics in Q2 2019 and held it in 7 quarters.
  • Schonfeld Strategic Advisors's Quince Therapeutics position peaked at $1.4M in Q3 2020.
  • 48 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.